The NWBO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the NWBO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The NWBO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View NWBO Detailed Price Forecast - CNN Money||View NWBO Detailed Summary - Google Finance|
|View NWBO Detailed Summary - Yahoo! Finance||View NWBO Stock Research & Analysis - Zacks.com|
|View NWBO Trends & Analysis - Trade-Ideas||View NWBO Major Holders - Barrons|
|View NWBO Call Transcripts - NASDAQ||View NWBO Breaking News & Analysis - Seeking Alpha|
|View NWBO Annual Report - CompanySpotlight.com||View NWBO OTC Short Report - OTCShortReport.com|
|View NWBO Fundamentals - TradeKing||View NWBO SEC Filings - Bar Chart|
|View Historical Prices for NWBO - The WSJ||View Performance/Total Return for NWBO - Morningstar|
|View the Analyst Estimates for NWBO - MarketWatch||View the Earnings History for NWBO - CNBC|
|View the NWBO Earnings - StockMarketWatch||View NWBO Buy or Sell Recommendations - MacroAxis|
|View the NWBO Bullish Patterns - American Bulls||View NWBO Short Pain Metrics - ShortPainBot.com|
|View NWBO Stock Mentions - StockTwits||View NWBO Stock Mentions - PennyStockTweets|
|View NWBO Stock Mentions - Twitter||View NWBO Investment Forum News - Investor Hub|
|View NWBO Stock Mentions - Yahoo! Message Board||View NWBO Stock Mentions - Seeking Alpha|
|View Insider Transactions for NWBO - SECform4.com||View Insider Transactions for NWBO - Insider Cow|
|View NWBO Major Holdings Summary - CNBC||View Insider Disclosure for NWBO - OTC Markets|
|View Insider Transactions for NWBO - Yahoo! Finance||View Institutional Holdings for NWBO - NASDAQ|
|View NWBO Stock Insight & Charts - FinViz.com||View NWBO Investment Charts - StockCharts.com|
|View NWBO Stock Overview & Charts - BarChart||View NWBO User Generated Charts - Trading View|
NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO
Posted on Thursday May 31, 2018
BETHESDA, Maryland, June 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer. Arrangements are being made for Dr. Bosch's presentation to be webcast. Details will be posted on the Company's website (www.nwbio.com) under the heading "Most Recent Presentations" when the arrangements are completed. It is anticipated that the webcast will be available for review after the presentation on the Company's website. This presentation is not an official presentation of the 2018 ASCO Annual Meeting. It is not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.
NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
Posted on Tuesday May 29, 2018
BETHESDA, Md., May 29, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer. The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with 69 co-authors in the peer reviewed Journal of Translational Medicine (JTM). The trial is ongoing while the data continue to mature, and the Company, the investigators and patients all remain blinded. The interim data set forth in the JTM publication are blinded aggregate data which include patients from both arms of the trial combined: the arm with 2/3 of the patients, who received standard of care plus DCVax-L, and the arm with 1/3 of the patients, who received standard of care plus a placebo. When the patients experienced tumor recurrence, all patients from both arms were allowed to cross over and start receiving DCVax-L, but without being unblinded as to what they had received before tumor recurrence. The patient population enrolled in the trial is similar to that in other recent trials, and more than 75% of the patients were over 50 years old (a factor associated with less favorable outcomes).
Northwest Biotherapeutics: 1Q Earnings Snapshot
Posted on Thursday May 17, 2018
The Bethesda, Maryland-based company said it had a loss of 9 cents per share. Losses, adjusted for one-time gains and costs, came to 6 cents per share. The cancer drug developer posted revenue of $132,000 ...
NW Bio Releases Vote Tallies From Special Shareholder Meeting
Posted on Tuesday May 01, 2018
BETHESDA, Md., May 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the vote tallies for the three proposals on the ballot at its Special Meeting of Shareholders held last Friday afternoon in Washington, DC. Proposal 1 was to raise the ceiling on the total number of authorized shares of common stock of the Company from 450 million to 1.2 billion. For this Proposal, only the common shares could vote. This Proposal was approved, with Yes votes from 87% of the votes cast (245,267,573), with 4% voting against (11,699,346), and 9% abstaining (25,836,335 votes). 30% did not vote (131,861,943). Proposal 2 was to raise the ceiling on the total number of authorized shares of preferred stock of the Company from 40 million to 100 million. For this Proposal, both the preferred stock and the common stock could vote. This Proposal was approved with Yes votes from 86% of the votes cast (327,025,901), with 7% voting against (27,266,121), and 7% abstaining (25,796,199).